Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK.
Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK; Department of Paediatric Haematology and Oncology, Royal Manchester Children's Hospital, Manchester, UK; Young Oncology Unit, The Christie NHS Foundation Trust, Manchester, UK.
Exp Hematol. 2022 Mar;107:1-8. doi: 10.1016/j.exphem.2021.12.398. Epub 2021 Dec 24.
High expression of the transcriptional regulator EVI1 encoded at the MECOM locus at 3q26 is one of the most aggressive oncogenic drivers in acute myeloid leukemia (AML) and carries a very poor prognosis. How EVI1 confers leukemic transformation and chemotherapy resistance in AML is subject to important ongoing clinical and experimental studies. Recent discoveries have revealed critical details on genetic mechanisms of the activation of EVI1 overexpression and downstream events of aberrantly high EVI1 expression. Here we review and discuss aspects concerning the protein interactions of EVI1 and the related proteins MDS-EVI1 and ΔEVI1 from the perspective of their potential for therapeutic intervention.
MECOM 基因座上转录调节因子 EVI1 的高表达是急性髓系白血病（AML）中最具侵袭性的致癌驱动因子之一，预后极差。EVI1 如何在 AML 中赋予白血病转化和化疗耐药性是正在进行的重要临床和实验研究的主题。最近的发现揭示了 EVI1 过表达的遗传机制激活和异常高 EVI1 表达的下游事件的关键细节。在这里，我们从治疗干预的角度回顾和讨论了 EVI1 及其相关蛋白 MDS-EVI1 和ΔEVI1 的蛋白相互作用的各个方面。
